AbbVie (NYSE:ABBV) jumps $18 billion Friday, beats Apogee as Skyrizi FDA decision comes Monday
AbbVie soared 4.2% to a 52-week high Friday, adding $18 billion in equity value—surpassing the $10.9 billion cash price for its Apogee buyout—even though the deal won’t boost adjusted EPS until 2032; FDA approval for expanded pediatric Skyrizi use came after the close, setting up Monday’s trading for a fresh catalyst.